Biotech initial public offerings in Europe have been as rare as hen’s teeth in the past few years so the news that Swiss antibiotics specialist BioVersys is looking to list has caught the eye.
The Basel-based company has announced plans for an IPO on the SIX Swiss stock exchange that aims to raise CHF80m ($88m) in the first quarter of this year